Applications

1786 – FreeStyle Libre 2 continuous glucose monitoring system for people with insulin dependent type 2 diabetes, gestational diabetes and type 3c diabetes

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status -
  • Type -
  • Pre-PASC consultation Closed
  • Pre-MSAC consultation Not yet started
  • Outcome Pending

Application details

Reason for application

National Diabetes Services Scheme funding.

Service or technology in this application

FreeStyle Libre 2 continuous glucose monitoring system (FSL2) is a monitoring system with two key components: a disposable 14-day sensor (inserted into subcutaneous tissue at the back of the upper arm) and a reader (using either a smartphone application or a physical reader). This sensor includes an inbuilt transmitter that transmits glucose data to the application or reader. It is designed to continuously measure glucose levels in the interstitial fluid and provides glucose trends, variability, and patterns across a 24-hour period.This helps people with type 2 diabetes (T2D) to manage their condition and reduce the risk of diabetes-related complications.

Type: Investigative technology

Medical condition this application addresses

T2D is a condition in which the body becomes resistant to the normal effects of insulin and gradually loses the capacity to produce enough insulin in the pancreas. This leads to high blood sugar (glucose) levels. T2D is the most common form of diabetes and is more likely to occur in those with a family history of the condition, although its development can also be associated with lifestyle factors.

Initially, T2D can often be managed with lifestyle modification such as healthy eating and regular exercise. However, many people with T2D will also need to take medication and many eventually require insulin injections to reduce the complications associated with the condition such as nerve damage, kidney disease and heart disease.

Consultation survey and deadlines

  • PASC consultation: Closed Friday 8 November 2024
    Any consultation received after this date will automatically be included in the MSAC consultation for this application.
  • MSAC consultation: TBA – please subscribe to the MSAC bulletin to be notified when this application is scheduled for MSAC consideration. The bulletin will also advise the closing date for consultation input.

Meetings to consider this application

  • PASC meeting: 12–13 December 2024
  • ESC meeting: -
  • MSAC meeting: -
     

Outcome details

The outcome of this application is pending.